Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo Controlled, Parallel Arm, Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of Lorundrostat in Subjects With Uncontrolled and Resistant Hypertension

NCT06153693 is registered in ClinicalTrials.gov with Mineralys Therapeutics Inc. as lead sponsor.

NCT NCT06153693
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06153693 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo Controlled, Parallel Arm, Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of Lorundrostat in Subjects With Uncontrolled and Resistant Hypertension
Lead sponsor
Mineralys Therapeutics Inc.
Phase
Phase 3
Overall status
Completed
Start date
November 22, 2023
Completion date
January 24, 2025
Enrollment
1,083 (actual)
Sites
184

Conditions

As the registry lists them; a condition with its own page is linked.

hypertension